Search

Your search keyword '"Hoffka, Gyula"' showing total 2 results
2 results on '"Hoffka, Gyula"'

1. Specificity Studies of the Venezuelan Equine Encephalitis Virus Non-Structural Protein 2 Protease Using Recombinant Fluorescent Substrates

Author

Bozóki, Beáta, Mótyán, János András, Hoffka, Gyula, Waugh, David S., and Tőzsér, József

Subjects
Viral Proteases, viruses, Venezuelan equine encephalitis virus, virus diseases, specificity, protease, biochemical phenomena, metabolism, and nutrition, Molecular Dynamics Simulation, Article, Substrate Specificity, lcsh:Chemistry, Encephalitis Virus, Venezuelan Equine, lcsh:Biology (General), lcsh:QD1-999, VEEV, nsP2, Catalytic Domain, Group IV virus, alphavirus, non-structural protein, alphaviral protease, lcsh:QH301-705.5, Oligopeptides
Abstract

The non-structural protein 2 (nsP2) of alphavirus Venezuelan equine encephalitis virus (VEEV) is a cysteine protease that is responsible for processing of the viral non-structural polyprotein and is an important drug target owing to the clinical relevance of VEEV. In this study we designed two recombinant VEEV nsP2 constructs to study the effects of an N-terminal extension on the protease activity and to investigate the specificity of the elongated enzyme in vitro. The N-terminal extension was found to have no substantial effect on the protease activity. The amino acid preferences of the VEEV nsP2 protease were investigated on substrates representing wild-type and P5, P4, P2, P1, P1&prime, and P2&prime, variants of Semliki forest virus nsP1/nsP2 cleavage site, using a His6-MBP-mEYFP recombinant substrate-based protease assay which has been adapted for a 96-well plate-based format. The structural basis of enzyme specificity was also investigated in silico by analyzing a modeled structure of VEEV nsP2 complexed with oligopeptide substrate. To our knowledge, in vitro screening of P1&prime, amino acid preferences of VEEV nsP2 protease remains undetermined to date, thus, our results may provide valuable information for studies and inhibitor design of different alphaviruses or other Group IV viruses.

Published
2020

2. Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease.

Author

Mótyán, János András, Mahdi, Mohamed, Hoffka, Gyula, and Tőzsér, József

Subjects
INTEGRASE inhibitors, PROTEASE inhibitors, COVID-19, SARS-CoV-2, HIV, HIV protease inhibitors, AMINO acid residues
Abstract

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome 2 (SARS-CoV-2), has been one of the most devastating pandemics of recent times. The lack of potent novel antivirals had led to global health crises; however, emergence and approval of potent inhibitors of the viral main protease (Mpro), such as Pfizer's newly approved nirmatrelvir, offers hope not only in the therapeutic front but also in the context of prophylaxis against the infection. By their nature, RNA viruses including human immunodeficiency virus (HIV) have inherently high mutation rates, and lessons learnt from previous and currently ongoing pandemics have taught us that these viruses can easily escape selection pressure through mutation of vital target amino acid residues in monotherapeutic settings. In this paper, we review nirmatrelvir and its binding to SARS-CoV-2 Mpro and draw a comparison to inhibitors of HIV protease that were rendered obsolete by emergence of resistance mutations, emphasizing potential pitfalls in the design of inhibitors that may be of important relevance to the long-term use of novel inhibitors against SARS-CoV-2. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results